ERBB2 and breast cancer: These negative results are contrary to what we have seen in HER2-positive breast cancer, for which the intensification of HER2 inhibition in first-line, as well as, the continuous exposition to an anti-HER2 therapy remains a standard of care in metastatic HER2-positive breast cancer patients setting.